Fig. 1

The upregulation of CPT1A is associated with increased malignancy and a worse prognosis in BC. (A) Representative IHC staining images of CPT1A. Scale bar: 200 μm (Up) and 50 μm (Down). (B) The positive and strong positive rate of CPT1A protein expression in adjacent normal (n = 29) and BC (n = 93) tissues. (C) Distribution of existing and absent LN metastasis in the CPT1A-low and CPT1A-high groups. (D) Kaplan-Meier survival analysis of BC in patients (n = 64) with low or high CPT1A expression (P = 0.001). (E) Correlation between CPT1A expression and the clinicopathological significance of patients with BC. (F) Overall survival (OS), recurrence-free survival (RFS), distant metastasis-free survival (DMFS), and post-progression survival (PPS) analysis of BC patients with CPT1A low or high expression in Kaplan-Meier databases. (G) Chemotherapy response rate and ROC analysis of CPT1A and BC patients in the Kaplan-Meier database. *P < 0.05, **P < 0.01